← All trials
NCT05455658
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 5, 2023
- Primary completion
- Apr 30, 2024
- Completion date
- Apr 30, 2024
- First posted
- Jul 13, 2022
- Last posted
- Dec 7, 2022
- Enrollment
- 33
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of WashingtonLead sponsor
- National Cancer Institute (NCI)Collaborator
- University of WashingtonOverall official - principal investigator
- University of WisconsinCollaborator
- University of WisconsinStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.